Free tool
FAERS Monitor: Priftin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021024 or its brand name (Priftin, Rifapentine). Reports on generic versions are filed under their own applications.
Reports
526
Serious
379
72% of reports
Hospitalization
168
Death reported
15
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug interaction67
- pyrexia66
- nausea52
- fatigue48
- vomiting44
- hypertension40
- off label use40
- headache32
- rash32
- dizziness31
- dyspnoea31
- influenza like illness27
- chills23
- hypotension23
- myalgia23
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 8 |
| 2013 | 15 |
| 2014 | 16 |
| 2015 | 20 |
| 2016 | 10 |
| 2017 | 73 |
| 2018 | 60 |
| 2019 | 50 |
| 2020 | 19 |
| 2021 | 58 |
| 2022 | 29 |
| 2023 | 13 |
| 2024 | 32 |
| 2025 | 73 |
| 2026 | 45 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,633 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug interactionSignal | 67 | 16.9 | 13.5 | 993 |
| influenza like illnessSignal | 27 | 13.1 | 9.1 | 291 |
| chillsSignal | 23 | 7.8 | 5.3 | 131 |
| pyrexiaSignal | 66 | 7.6 | 6.1 | 380 |
| hypertensionSignal | 40 | 7.6 | 5.6 | 223 |
| myalgiaSignal | 23 | 5.4 | 3.6 | 79 |
| hypotensionSignal | 23 | 4.6 | 3.1 | 62 |
| vomitingSignal | 44 | 3.7 | 2.8 | 88 |
| rashSignal | 32 | 2.9 | 2.1 | 40 |
| nauseaSignal | 52 | 2.6 | 2.0 | 53 |
| dizzinessSignal | 31 | 2.5 | 1.8 | 27 |
| fatigueSignal | 48 | 2.5 | 1.9 | 42 |
| dyspnoeaSignal | 31 | 2.2 | 1.6 | 19 |
| headacheSignal | 32 | 2.0 | 1.5 | 16 |
| off label use | 40 | 1.8 | 1.4 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.